Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma
Keywords: نئوتوزوماب; Nasopharyngeal carcinoma; IMRT; Concurrent chemoradiotherapy; Nimotuzumab; Cetuximab; Survival outcome; Adverse events;